Lumenis Dynamic Muscle Stimulation Technology Shows Promise for Treating Dry Eye Disease Through Lower Lid Laxity Correction
核心洞察
A clinical study of 30 patients demonstrated that Lumenis (搜索)'s Dynamic Muscle Stimulation technology (搜索) significantly improved lower lid laxity and blinking quality in dry eye disease patients.
The proportion of patients with normal lower lid function increased from 3% to 80% after four weekly treatments, with dramatic improvements in blink rate and meibomian gland function.
The non-invasive treatment resulted in a 286% increase in tear break-up time and 53% decrease in dry eye symptom scores, offering an alternative to surgical correction.
A new clinical study has demonstrated that Lumenis (搜索)'s Dynamic Muscle Stimulation technology (搜索) (DMSt) effectively addresses lower lid laxity and improves blinking quality in patients with dry eye disease, potentially offering a non-invasive alternative to surgical intervention for this common but underdiagnosed condition.
The research, titled "Dynamic Muscle Stimulation of the Periorbital Area for Improvement of Blinking in Dry Eye Patients," was published in Clinical Ophthalmology and led by James Chelnis, MD, FACS, an oculofacial plastic and reconstructive surgeon at Manhattan Face & Eye (搜索).
Addressing an Underdiagnosed Contributor to Dry Eye Disease
Lower lid laxity represents a highly prevalent yet often overlooked condition that can significantly impact ocular surface health. The condition may be associated with natural aging, sleep apnea, floppy lids, nocturnal lagophthalmos, and certain variations in orbital anatomy. Patients with eyelid laxity are more than twice as likely to develop severe ocular surface symptoms and signs of dry eye disease due to the lid's diminished ability to maintain proper tear film distribution, which can exacerbate dryness and inflammation.
Historically, treatment options for lower lid laxity have been limited to conservative approaches such as nighttime ointments, taping, and blinking exercises, or surgical correction in more advanced cases.
Clinical Study Results
The study enrolled 30 patients with lower lid laxity and moderate to severe dry eye disease who received four weekly DMSt treatments. Outcomes were assessed one month after the fourth treatment, revealing significant improvements across multiple parameters:
Lower Lid Function Improvements:
- The proportion of subjects displaying normal Lower Lid Distraction Test results increased from 3% at baseline to 80% at follow-up
- 93% of patients demonstrated normal Snap-Back Test results at follow-up, compared to 30% at baseline
Blinking Function Enhancement:
- 93% of subjects demonstrated normal blink rate at follow-up, compared to 37% at baseline
- 73% of subjects demonstrated normal blinking quality at follow-up, compared to 0% at baseline
Ocular Surface Health Metrics:
- 78% decrease in modified Meibomian Gland Score, indicating improved meibomian gland function
- 286% increase in tear break-up time, demonstrating enhanced tear film stability
- 53% decrease in Ocular Surface Disease Index scores
Technology and Mechanism of Action
The DMSt technology, which powers Lumenis (搜索)'s OptiLIFT (搜索) device introduced in early 2025, works by activating facial muscles with electrical impulses, tightening and toning the periorbital muscle to create improved eyelid function. The system includes radiofrequency components that deliver heat to skin layers to enhance collagen formation.
Study authors noted that DMSt may improve blood flow in addition to reducing lower lid laxity, potentially enhancing blinking efficiency and tear film stability. "Unlike two other technologies in this space – intense pulsed light and radiofrequency – this technology can help address deficits in eyelid position and movement, particularly useful for older patients or those with floppy or mispositioned eyelids," the researchers stated.
Clinical Significance and Future Directions
"The results of our study underscore a significant advancement in how we manage dry eye disease by addressing a common underlying contributor—lower lid laxity," said Dr. Chelnis. "Lumenis (搜索)'s Dynamic Muscle Stimulation empowers practitioners by offering a method of treating the structural elements contributing to ocular surface disease – a method that supplements and enhances our ability to effect root causes of our patients' symptoms."
The researchers acknowledged several study limitations, including the lack of a control group, small sample size, modest follow-up duration, and qualitative assessment of some outcomes. They emphasized the need for further studies with larger sample sizes, longer follow-up periods, control groups, and quantitative measurements of blinking parameters to better evaluate this novel approach and understand its mechanism of action.